Allergan The health care company reported earlier this month earnings of $279.8 million, or 92 cents a share, up from year-ago earnings of $263.1 million, or 87 cents. "Management sounded confident in the potential for its current products and pipeline to drive strong growth," Bank of America Merrill Lynch analysts wrote in a Feb. 9 report. "Re-loading the pipeline through both internal and external efforts (supported by strong cash flow) will be a priority for 2012. We are maintaining our Buy rating, as we believe that AGN's diversified revenue base, strong pipeline, focus on innovation, and productive R&D engine position the company well for continued strong and sustainable revenue and EPS growth." Forward Annual Dividend Yield: 0.2% Rated "A- (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin was basically the same as the prior year. Allergan is extremely liquid. Its Quick Ratio is 3.47, which shows the company can meet its short-term cash needs. In the fourth quarter, stockholders' net worth increased 11.60% from the prior year. TheStreet Ratings' price target is $109.39. The stock closed Friday at $87.91 and has risen slightly year to date.